{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:18:03Z","timestamp":1783984683256,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cpet.2023.12.006","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T09:21:57Z","timestamp":1704792117000},"page":"197-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["PET\/Computed Tomography Transformation of Oncology"],"prefix":"10.1016","volume":"19","author":[{"given":"Jorge D.","family":"Oldan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Kimryn","family":"Rathmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Khandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.cpet.2023.12.006_bib2","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1158\/1078-0432.CCR-15-2115","article-title":"Alternate metabolic Programs define regional Variation of Relevant biological features in renal cell carcinoma Progression","volume":"22","author":"Brooks","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2023.12.006_bib3","doi-asserted-by":"crossref","first-page":"43356","DOI":"10.1038\/srep43356","article-title":"Associations between tumor Vascularity, Vascular Endothelial growth Factor expression and PET\/MRI radiomic Signatures in primary clear-cell-renal-cell-carcinoma: Proof-of-Concept study","volume":"7","author":"Yin","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.006_bib4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.urology.2009.06.105","article-title":"The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response","volume":"75","author":"Cowey","year":"2010","journal-title":"Urology"},{"issue":"7858","key":"10.1016\/j.cpet.2023.12.006_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.cpet.2023.12.006_bib6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jnci\/djj362","article-title":"Rising incidence of small renal masses: a need to reassess treatment effect","volume":"98","author":"Hollingsworth","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.006_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.urology.2012.12.049","article-title":"Multiphasic enhancement patterns of small renal masses (<\/=4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma","volume":"81","author":"Pierorazio","year":"2013","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.006_bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1148\/rg.284065018","article-title":"MR imaging of renal masses: correlation with findings at surgery and pathologic analysis","volume":"28","author":"Pedrosa","year":"2008","journal-title":"Radiographics"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","article-title":"Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma","volume":"12","author":"Wang","year":"2012","journal-title":"Cancer Imag"},{"issue":"11","key":"10.1016\/j.cpet.2023.12.006_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4329\/wjr.v5.i11.436","article-title":"MDCT imaging following nephrectomy for renal cell carcinoma: protocol optimization and patterns of tumor recurrence","volume":"5","author":"Coquia","year":"2013","journal-title":"World J Radiol"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.006_bib11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2967\/jnumed.118.215434","article-title":"Unspecific (18)F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone Scanning, and MRI Triple Validation in patients with Biochemical recurrence of prostate cancer","volume":"64","author":"Seifert","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.006_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1464-410X.2008.08150.x","article-title":"Significance of 18F-fluorodeoxyglucose positron-emission tomography\/computed tomography for the postoperative surveillance of advanced renal cell carcinoma","volume":"103","author":"Park","year":"2009","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12885-022-09239-3","article-title":"Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.006_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MNM.0000000000000618","article-title":"Diagnostic performance of 18F-FDG PET or PET\/CT in restaging renal cell carcinoma: a systematic review and meta-analysis","volume":"38","author":"Ma","year":"2017","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.006_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/iju.IJU_268_20","article-title":"Role of positron emission tomography\/computed tomography in the evaluation of renal cell carcinoma","volume":"37","author":"Jena","year":"2021","journal-title":"Indian J Urol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","article-title":"PET imaging in renal cancer","volume":"31","author":"Lindenberg","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.006_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020354","article-title":"Advances in imaging-based biomarkers in renal cell carcinoma: a Critical analysis of the current Literature","volume":"15","author":"Posada Calderon","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.006_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11934-019-0932-2","article-title":"Role of positron emission tomography imaging in Metabolically active renal cell carcinoma","volume":"20","author":"Karivedu","year":"2019","journal-title":"Curr Urol Rep"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.006_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cam4.102","article-title":"FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer","volume":"2","author":"Chen","year":"2013","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrurol.2010.234","article-title":"Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC","volume":"8","author":"Yamasaki","year":"2011","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.006_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00345-018-2439-8","article-title":"Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis","volume":"37","author":"Crozier","year":"2019","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000488200","article-title":"Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis","volume":"95","author":"Ha","year":"2018","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.cpet.2023.12.006_bib24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00345-016-1772-z","article-title":"The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis","volume":"34","author":"Soubra","year":"2016","journal-title":"World J Urol"},{"issue":"12","key":"10.1016\/j.cpet.2023.12.006_bib25","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/cancers14123000","article-title":"PET-CT in clinical Adult oncology-IV. Gynecologic and genitourinary malignancies","volume":"14","author":"Salem","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.006_bib26","first-page":"562","article-title":"Diagnostic evaluation of 18F-FDG PET\/CT imaging in recurrent or residual urinary bladder cancer: a meta-analysis","volume":"17","author":"Xue","year":"2020","journal-title":"Urol J"},{"issue":"7","key":"10.1016\/j.cpet.2023.12.006_bib27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/RLU.0000000000004639","article-title":"Predictive value of 18 F-FDG PET\/CT for assessment of tumor response to Neoadjuvant chemotherapy in bladder cancer","volume":"48","author":"Ko","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.006_bib28","first-page":"1214","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib29","first-page":"52","article-title":"A\u00a0phase 2\/3 prospective Multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"11","key":"10.1016\/j.cpet.2023.12.006_bib30","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical Prostatectomy and pelvic lymph node Dissection: a Multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.006_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib32","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/ijms22031120","article-title":"PEG linker Length Strongly Affects tumor cell Killing by PEGylated carbonic anhydrase inhibitors in hypoxic carcinomas expressing carbonic anhydrase IX","volume":"22","author":"Mondal","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"32","key":"10.1016\/j.cpet.2023.12.006_bib33","doi-asserted-by":"crossref","first-page":"33733","DOI":"10.18632\/oncotarget.5254","article-title":"Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"35","key":"10.1016\/j.cpet.2023.12.006_bib34","doi-asserted-by":"crossref","first-page":"56471","DOI":"10.18632\/oncotarget.10602","article-title":"[64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma","volume":"7","author":"Minn","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00261-015-0599-1","article-title":"PET\/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study","volume":"41","author":"Turkbey","year":"2016","journal-title":"Abdom Radiol (NY)"},{"issue":"6_suppl","key":"10.1016\/j.cpet.2023.12.006_bib36","doi-asserted-by":"crossref","first-page":"LBA602","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA602","article-title":"Results from phase 3 study of 89Zr-DFO-girentuximab for PET\/CT imaging of clear cell renal cell carcinoma (ZIRCON)","volume":"41","author":"Shuch","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13550-017-0329-5","article-title":"Correlation of (99m)Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression","volume":"7","author":"Rowe","year":"2017","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.006_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/RLU.0000000000000670","article-title":"Initial experience using 99mTc-MIBI SPECT\/CT for the differentiation of oncocytoma from renal cell carcinoma","volume":"40","author":"Rowe","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2015.08.056","article-title":"Prospective evaluation of (99m)Tc-sestamibi SPECT\/CT for the diagnosis of renal oncocytomas and Hybrid oncocytic\/Chromophobe tumors","volume":"69","author":"Gorin","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13550-017-0277-0","article-title":"Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?","volume":"7","author":"Rowe","year":"2017","journal-title":"EJNMMI Res"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.006_bib41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.006_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00345-015-1631-3","article-title":"Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world","volume":"34","author":"Taguchi","year":"2016","journal-title":"World J Urol"},{"issue":"29","key":"10.1016\/j.cpet.2023.12.006_bib43","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.cpet.2023.12.006_bib44","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma Progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.006_bib45","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin Plus pembrolizumab in Previously Untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.cpet.2023.12.006_bib47","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with Previously Untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.cpet.2023.12.006_bib48","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET\/CT imaging of advanced urothelial carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.cpet.2023.12.006_bib49","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2023.12.006_bib50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.intimp.2018.12.018","article-title":"Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatments for urothelial carcinoma patients: a meta-analysis","volume":"67","author":"Rui","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.cpet.2023.12.006_bib51","doi-asserted-by":"crossref","first-page":"920021","DOI":"10.3389\/fimmu.2022.920021","article-title":"From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1\/PD-L1 blockades","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.cpet.2023.12.006_bib52","doi-asserted-by":"crossref","first-page":"e056708","DOI":"10.1136\/bmjopen-2021-056708","article-title":"ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0\/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET\/CT in stage III NSCLC patients receiving chemoradiation study protocol","volume":"12","author":"Hegi-Johnson","year":"2022","journal-title":"BMJ Open"},{"issue":"22","key":"10.1016\/j.cpet.2023.12.006_bib53","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-22-1547","article-title":"ImmunoPET imaging with 89Zr-labeled Atezolizumab Enables in\u00a0Vivo evaluation of PD-L1 in Tumorgraft models of renal cell carcinoma","volume":"28","author":"Mulgaonkar","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cpet.2023.12.006_bib54","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-22-1931","article-title":"Gallium-68-labeled peptide PET quantifies tumor Exposure of PD-L1 therapeutics","volume":"29","author":"Mishra","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.006_bib56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-Humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell Lung cancer patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.006_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060747","article-title":"Development of radiotracers for imaging of the PD-1\/PD-L1 Axis","volume":"15","author":"Krutzek","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib58","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cas.13137","article-title":"Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses","volume":"108","author":"Komohara","year":"2017","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.006_bib59","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.cpet.2023.12.006_bib60","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2006.07.8097","article-title":"Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors","volume":"25","author":"Milowsky","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2023.12.006_bib61","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.urology.2018.02.011","article-title":"Photorealistic 3-Dimensional Cinematic Rendering of clear cell renal cell carcinoma from Volumetric computed tomography data","volume":"115","author":"Rowe","year":"2018","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.cpet.2023.12.006_bib62","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12149-015-1017-z","article-title":"Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET\/CT","volume":"29","author":"Rowe","year":"2015","journal-title":"Ann Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2023.12.006_bib63","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s00259-019-04432-2","article-title":"The use of (68)Ga-PET\/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma","volume":"46","author":"Raveenthiran","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2023.12.006_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RLU.0000000000000995","article-title":"Detection of 18F-FDG PET\/CT occult lesions with 18F-DCFPyL PET\/CT in a patient with metastatic renal cell carcinoma","volume":"41","author":"Rowe","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib65","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2967\/jnmt.122.264014","article-title":"(18)F-FDG PET\/CT vs. (68)Ga-PSMA-11 PET\/CT in evaluation of distant metastatic disease in recurrent Renal Cell Carcinoma","volume":"51","author":"Parghane","year":"2023","journal-title":"J\u00a0Nucl Med Technol"},{"issue":"6","key":"10.1016\/j.cpet.2023.12.006_bib66","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of Nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the Field, and a Call to Arms","volume":"59","author":"Salas Fragomeni","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2023.12.006_bib67","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11307-018-1271-2","article-title":"Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [(18)F]DCFPyL PET\/CT","volume":"21","author":"Yin","year":"2019","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"10.1016\/j.cpet.2023.12.006_bib68","first-page":"333","article-title":"Molecular imaging in oncology: current impact and future directions","volume":"72","author":"Rowe","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cpet.2023.12.006_bib69","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-med-062117-073027","article-title":"Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the Bench to advanced clinical applications","volume":"70","author":"Rowe","year":"2019","journal-title":"Annu Rev Med"},{"issue":"9","key":"10.1016\/j.cpet.2023.12.006_bib70","doi-asserted-by":"crossref","first-page":"817","DOI":"10.21037\/atm-2020-mi-09","article-title":"Artificial intelligence in molecular imaging: at the crossroads of revolutions in medical diagnosis","volume":"9","author":"Rowe","year":"2021","journal-title":"Ann Transl Med"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:13:20Z","timestamp":1761563600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859823000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1556859823000998"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2023.12.006","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/Computed Tomography Transformation of Oncology","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2023.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}